GLP-1 and kidney health: FLOW trial evidence

For years, doctors thought of GLP-1 drugs like semaglutide as tools for blood sugar and weight. Then the FLOW trial changed the conversation. It showed that once-weekly semaglutide slowed kidney disease in people with type 2 diabetes, and in January 2025 the FDA added a kidney-protection indication to the Ozempic label. This guide walks through what the kidney evidence actually says, where it's strong, and where it's still thin.

Why the kidneys came into the picture

Your kidneys filter about 180 liters of blood a day. In type 2 diabetes, high blood sugar and high blood pressure slowly damage the tiny filters (glomeruli) inside them. Protein starts leaking into the urine. Filtering capacity, measured as eGFR (estimated glomerular filtration rate), drifts down year after year. Left alone, this path ends in kidney failure, dialysis, or a transplant.

For decades the only drugs proven to slow this were blood-pressure medicines that act on the renin-angiotensin system (ACE inhibitors and ARBs). Then SGLT2 inhibitors arrived and added a second protective layer. GLP-1 receptor agonists are now the third class with hard kidney outcome data behind them. That's a big deal, because diabetic kidney disease is the leading cause of kidney failure worldwide.

What GLP-1 drugs are, in one paragraph

GLP-1 receptor agonists copy a gut hormone your body makes after eating. They lower blood sugar, slow stomach emptying, and dial down appetite. Semaglutide is sold as Ozempic and Rybelsus (diabetes) and Wegovy (weight). Tirzepatide (Mounjaro, Zepbound) is a related drug that hits two receptors. For a fuller primer on how these compare, see our semaglutide vs tirzepatide head-to-head comparison.

How GLP-1 drugs may protect the kidney

The honest answer: the mechanism is not fully nailed down, and it's almost certainly more than one thing working at once. Here's what the evidence points to.

Lower blood sugar and blood pressure. Better glucose control and modest drops in blood pressure ease the strain on the glomeruli. But the kidney benefit in trials is bigger than glucose lowering alone can explain, which is the key clue that something else is going on.

Less glomerular hyperfiltration. Early in diabetic kidney disease, the filters work too hard. GLP-1 drugs appear to calm this overwork. You can actually see it in the data: when people start the drug, eGFR dips slightly in the first weeks, then declines more slowly than placebo over the long run. That "dip then preserve" pattern is shared by every drug class proven to protect kidneys, including ACE inhibitors and SGLT2 inhibitors.

Less inflammation and scarring. In animal and lab studies, GLP-1 drugs reduce kidney inflammation, oxidative stress, and fibrosis (scar tissue). These effects seem partly independent of blood sugar. The catch is that animal-to-human translation is unreliable, so this part of the story is suggestive, not settled.

Weight loss. Excess weight strains the kidneys directly. Losing 10 to 15 percent of body weight likely helps, though trials have struggled to fully separate weight effects from drug effects. Obesity raises pressure inside the abdomen, pushes up filtration demand, and feeds the inflammation that scars kidney tissue. Shedding weight unwinds some of that. But here's the wrinkle: in FLOW, the dose was 1.0 mg, not the higher weight-loss doses, and the kidney benefit appeared early, before most of the weight came off. That timing argues the protection isn't only about the scale.

One more honest note on mechanism. Researchers still can't fully say how much of the benefit is the drug acting directly on the kidney versus the drug improving the whole metabolic system, which then spares the kidney. The two are tangled together. Most experts lean toward "both," but if you read a confident single-cause explanation anywhere, it's getting ahead of the data.

A 2023 post hoc analysis pooling the SUSTAIN-6 and PIONEER-6 trials found people on semaglutide had more stable kidney function than placebo, with a gentler eGFR slope over time (Tuttle et al., Kidney International, 2023). A later analysis showed this kidney benefit held up across different starting levels of blood sugar, blood pressure, weight, and albuminuria (NDT, 2025). For a wider tour of the proposed mechanisms across studies, see the GLP-1 nephroprotection literature on PubMed.

The FLOW trial: the centerpiece of the evidence

Everything before FLOW was a hint. FLOW was the first large trial designed specifically to test whether a GLP-1 drug protects the kidney. It's the reason the FDA changed the Ozempic label, so it deserves a close look.

What FLOW tested

FLOW (Evaluate Renal Function with Semaglutide Once Weekly) randomized 3,533 adults with type 2 diabetes and existing chronic kidney disease to either semaglutide 1.0 mg once weekly or placebo, both on top of standard care. Everyone already had meaningful kidney damage at the start, with reduced eGFR and high protein in the urine. The trial was stopped early in 2023 for clear benefit and published in 2024 (Perkovic et al., NEJM, 2024).

The headline result

FLOW trial outcome	Semaglutide vs placebo	What it means
Primary composite (kidney failure, 50%+ eGFR loss, kidney or CV death)	24% lower risk (HR 0.76, 95% CI 0.66–0.88; p=0.0003)	Fewer people reached kidney failure or died
Annual eGFR decline	1.16 mL/min/1.73m² slower per year	Kidneys aged more slowly
Albuminuria (protein in urine)	~38% greater reduction	Less filter leakage
Major cardiovascular events	18% lower risk	Fewer heart attacks/strokes
Death from cardiovascular causes	~29% lower risk	A mortality benefit
Death from any cause	20% lower risk	People lived longer

Put plainly: treating roughly 20 people for about three years prevented one major kidney or cardiovascular event. The follow-up averaged 3.4 years. The benefit showed up across the spectrum of kidney disease severity in the trial, not just in the mildest cases.

Reading the numbers carefully

A few details separate hype from substance. The primary outcome is a composite, meaning it bundles several events together: kidney failure, a 50 percent drop in eGFR, and death from kidney or cardiovascular causes. Composites are standard in this kind of trial because any single event is rare, but they can hide which piece is driving the result. In FLOW, the kidney-specific pieces and the death pieces both moved in the right direction, which is more convincing than a result carried by just one component.

The eGFR slope number deserves attention too. A difference of 1.16 mL/min/1.73m² per year sounds small. But kidney disease is a slow grind measured in decades, and shaving a bit off the yearly decline compounds. Over many years, that gap is the difference between staying off dialysis and not. Slope is also a more sensitive early signal than waiting for hard failure events, which is why regulators increasingly accept it.

And the albuminuria drop matters because protein in the urine is both a marker of damage and a driver of it. Less leakage tends to predict slower long-term decline. So the three findings reinforce each other rather than standing alone.

How strong is this evidence?

Strong, with honest caveats:

Trial quality is high. FLOW was a large, double-blind, placebo-controlled, randomized trial run across 28 countries. That's the gold standard.
The endpoints are hard. Kidney failure and death are not soft surrogate measures. They matter to patients.
It was funded by Novo Nordisk, the maker of semaglutide. Industry funding doesn't void a result, but it's a known source of bias in design, analysis, and reporting. Worth keeping in mind.
The population was specific. Everyone had type 2 diabetes AND established CKD with protein in the urine. FLOW does NOT prove semaglutide protects the kidneys of people without diabetes, or people with healthy kidneys, or people taking it purely for weight loss. Those questions are still open.
Most participants were not on an SGLT2 inhibitor at the start, which raises a fair question (more on that below).

The CV death and all-cause mortality benefits echo what we've seen in cardiovascular outcome trials. If you want that side of the story, see our piece on the GLP-1 heart attack recovery study.

Where GLP-1 fits next to other kidney-protective drugs

GLP-1 drugs did not replace anything. They got added to a stack. Here's how the main players compare for diabetic kidney disease.

Drug class	Kidney benefit proven?	Main mechanism	Typical role
ACE inhibitors / ARBs	Yes, long established	Lower glomerular pressure	First-line foundation
SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin)	Yes, strong outcome trials	Reduce hyperfiltration via the kidney tubule	First-line for diabetic CKD
GLP-1 receptor agonists (semaglutide)	Yes, FLOW trial	Multiple: glucose, weight, anti-inflammatory, hemodynamic	Added on top, especially with obesity
Nonsteroidal MRAs (finerenone)	Yes, in diabetic CKD	Block aldosterone-driven inflammation/fibrosis	Add-on for residual albuminuria

The 2024 KDIGO guidelines (the global kidney standard) recommend a long-acting GLP-1 receptor agonist for people with type 2 diabetes and CKD who need more glucose control beyond metformin and an SGLT2 inhibitor, or who can't take those drugs (KDIGO Diabetes and CKD guideline). Note the order: GLP-1 is usually an add-on, not the foundation.

Do you stack GLP-1 and SGLT2 inhibitors together?

This is the live question. SGLT2 inhibitors and GLP-1 drugs appear to protect the kidney through different routes, which suggests their benefits could add up rather than overlap. A FLOW sub-analysis looked at people already taking an SGLT2 inhibitor and found semaglutide's kidney benefit appeared consistent whether or not they were on one. That's reassuring but not the same as a trial built to test the combination head-on. For now, "use both when appropriate" is a reasonable guideline-backed position, but the dedicated combination trial data is still maturing.

What about tirzepatide and the newer drugs?

FLOW tested semaglutide. It did not test tirzepatide (Mounjaro, Zepbound), the dual-receptor drug that often drives more weight loss. Tirzepatide has shown kidney-friendly signals in its diabetes trials, including reduced albuminuria, but it does not yet have a dedicated kidney outcome trial of FLOW's scale. So the FDA kidney indication belongs to semaglutide alone for now. Assuming tirzepatide protects the kidney the same way is a reasonable guess, not a proven fact. The same caution applies to the wave of newer agents, including oral GLP-1 pills and triple-agonist drugs in late-stage testing. Their kidney data is early or absent.

This is a recurring theme with GLP-1 drugs: a benefit proven for one molecule in one population gets stretched, in headlines and clinics, to the whole class. Sometimes the stretch is fair. Sometimes it isn't. The kidney indication is a good example of how narrow the actual evidence can be even when the buzz is broad.

GLP-1 drugs and kidney stones: a separate, weaker story

Kidney stones are a different problem from chronic kidney disease, and the evidence here is much thinner. Obesity and metabolic syndrome raise stone risk, so in theory a drug that drives major weight loss might lower it. The early signals are interesting but should be read with caution.

What the data suggests. Several real-world cohort studies (mostly presented at urology meetings, not yet large randomized trials) report lower rates of stone events in GLP-1 users versus non-users, especially among people with obesity. One proposed mechanism is changes in urine chemistry, such as lower urinary oxalate. A few analyses also suggest semaglutide may slow the growth of existing stones compared with other GLP-1 drugs.

What undercuts it. When semaglutide was compared directly with metformin in a large retrospective study, researchers found no significant difference in the risk of new urinary stone disease. And there's a competing worry: rapid weight loss of any kind, plus the dehydration that GI side effects can cause, can in theory raise stone risk. The net effect is genuinely unsettled.

Kidney stone question	What the evidence shows	Confidence
Do GLP-1 drugs lower stone risk?	Some cohort studies show fewer stone events, mostly in obesity	Low — observational, not randomized
Does semaglutide beat metformin for stones?	One large study found no significant difference	Low to moderate
Could dehydration raise stone risk?	Plausible during GI side effects and rapid weight loss	Theoretical
Bottom line	Possibly protective in obesity; far from proven	Weak overall

The honest takeaway: do not start a GLP-1 drug to prevent kidney stones. There's no outcome trial supporting that. If you have a stone history, hydration matters more than the drug choice. You can scan the current GLP-1 and kidney stone studies on PubMed, and you'll notice how few there are.

Safety: the kidney risks worth knowing

GLP-1 drugs are not risk-free for the kidney, and the risk profile is mostly indirect.

Acute kidney injury (AKI) from dehydration. This is the one to watch. The drugs commonly cause nausea, vomiting, and diarrhea, especially when you first start or move up a dose. If those side effects get bad and you stop drinking enough fluids, you can become dehydrated. Dehydration can trigger acute kidney injury. The FDA label notes post-marketing reports of AKI and worsening kidney function, and most occurred in people who'd had GI side effects. The drug itself isn't directly poisoning the kidney; the dehydration is the culprit. See the broader GLP-1 and acute kidney injury literature.

The early eGFR dip. When you start the drug, your eGFR may drop a bit. This is usually expected and not a sign of damage; it's the same hemodynamic effect that signals long-term protection. Your doctor may check kidney labs after you start.

Practical safety rules:

Sip fluids steadily, especially in the first weeks and after any dose increase.
If you have severe vomiting or diarrhea, contact your clinician. Don't just push through it.
Titrate the dose slowly. Rushing the dose drives the worst GI side effects.
People with existing kidney impairment should be monitored more closely.

For the full side-effect picture beyond the kidneys, see our GLP-1 side effects complete guide.

Who the kidney evidence actually applies to

This is where overstatement creeps in, so let's be precise.

Best-supported group: Adults with type 2 diabetes AND established chronic kidney disease (reduced eGFR plus protein in the urine). This is exactly the FLOW population and the FDA-approved indication. The FDA approved Ozempic in January 2025 to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death in this group (National Kidney Foundation; Novo Nordisk announcement).

Plausible but unproven: People with type 2 diabetes and early kidney changes, or people with obesity-related kidney disease without diabetes. Mechanistically it could help. But FLOW didn't enroll them, so it's an extrapolation.

No kidney claim: People with healthy kidneys taking a GLP-1 drug only for weight loss. They may get general metabolic benefits, but there's no kidney outcome trial telling them their kidneys are being protected. Don't sell it as kidney protection.

GLP-1 drugs interact with several conditions across the body, and the kidney story is one slice of a bigger picture. Our GLP-1 by subgroup overview covers how the evidence shifts for PCOS, prediabetes, fatty liver, and cardiovascular disease. On the liver side specifically, the Mounjaro and fatty liver (MASH) evidence shows a similar pattern of organ-specific trials.

The bottom line

The kidney evidence for GLP-1 drugs is real and, for one specific group, strong. FLOW showed semaglutide cut the risk of kidney failure, kidney decline, and cardiovascular death by about a quarter in people with type 2 diabetes and chronic kidney disease. That's a genuine, FDA-recognized benefit backed by a high-quality trial, tempered by the fact that the maker funded it.

Outside that group, the picture gets fuzzier fast. Kidney protection in non-diabetics, in healthy-kidney weight-loss users, and against kidney stones is unproven, theoretical, or based on weak observational data. The main kidney safety concern is dehydration-driven acute injury, which is manageable with fluids and slow dosing. If you have diabetic kidney disease, this is a conversation worth having with your nephrologist. If you don't, treat the kidney-protection angle as a maybe, not a promise.

Frequently Asked Questions

Does semaglutide protect the kidneys in people without diabetes?

We don't know yet. The FLOW trial only enrolled people with type 2 diabetes and chronic kidney disease, so the proven benefit applies to that group. There's biological reason to think it might help others, but no large trial has tested it in people without diabetes. Treat any non-diabetic kidney claim as unproven.

How much did semaglutide slow kidney decline in the FLOW trial?

Semaglutide cut the risk of the primary kidney-and-death outcome by 24 percent and slowed the yearly drop in eGFR by about 1.16 mL/min/1.73m² compared with placebo. It also reduced protein leakage into the urine by roughly 38 percent over a median follow-up of about 3.4 years.

Can GLP-1 drugs cause kidney damage?

Indirectly, yes. The bigger risk is dehydration from nausea, vomiting, or diarrhea, which can trigger acute kidney injury. The drug itself isn't directly toxic to the kidney. Drinking enough fluids, titrating the dose slowly, and calling your doctor if GI side effects get severe sharply lower this risk.

Do GLP-1 drugs prevent kidney stones?

The evidence is weak and mixed. Some real-world studies show fewer stone events in GLP-1 users with obesity, possibly from weight loss and urine chemistry changes. But one large study found no difference versus metformin, and rapid weight loss with dehydration could theoretically raise risk. Don't start a GLP-1 drug to prevent stones.

Should I take a GLP-1 drug and an SGLT2 inhibitor together for my kidneys?

Often, yes, if you have diabetic kidney disease. The two classes appear to protect the kidney through different mechanisms, so their benefits may add up, and guidelines support using both when appropriate. A dedicated trial of the combination is still maturing, so discuss the specifics with your nephrologist.

This article is for general education and is not medical advice. GLP-1 medications and kidney disease management require personalized care. Talk to your doctor or nephrologist before starting, stopping, or changing any medication.